nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2011 | Original Article

¹⁸F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study

verfasst von: Sheng-Chieh Chan, Hung-Ming Wang, Tzu-Chen Yen, Chien-Yu Lin, Shy-Chyi Chin, Chun-Ta Liao, Yau-Yau Wai, Jiun-Jie Wang, Shu-Hang Ng

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this prospective study was to compare the diagnostic value of ¹⁸F-FDG PET/CT and 3.0-T whole-body MRI (WB-MRI) for the assessment of distant metastases and second primary cancer (SPC) in patients with untreated oropharyngeal or hypopharyngeal squamous cell carcinoma (OHSCC).

Methods

A total of 103 patients were enrolled. All participants underwent 3.0-T WB-MRI and ¹⁸F-FDG PET/CT. The diagnostic capabilities of the two imaging modalities were compared using the area under the receiver-operating-characteristic curve. Histology and follow-up data were used as the reference standard.

Results

Of the 103 patients, 18 (17.5%) were found to have either distant metastases or SPC. A total of 21 sites were involved. On a lesion-based analysis, ¹⁸F-FDG PET/CT showed a trend toward a higher sensitivity than WB-MRI (81.0% vs. 61.9%, P = 0.125). The area under the curve (AUC) for PET/CT was also higher than for WB-MRI, although not significantly so (0.932 vs. 0.866, P = 0.189). On a patient-based analysis, the sensitivity of WB-MRI was lower than that of PET/CT (66.7% vs. 83.3%, P = 0.625). In terms of diagnostic capability, the AUC was higher for PET/CT than WB-MRI (0.886 vs. 0.813, P = 0.355). The maximal SUV of the regional lymph nodes (SUVn) above the median value (8.7 g/ml) was significantly associated with the occurrence of distant metastasis (P = 0.026).

Conclusion

¹⁸F-FDG PET/CT showed a consistent trend toward higher sensitivity and diagnostic capability than 3.0-Tesla WB-MRI for the detection of distant metastases and SPCs in patients with untreated OHSCC. Our data also suggest that SUVn assessed by PET/CT can provide additional information for the prediction of distant metastases

Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol. 2001;19:1358–62.PubMed

Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202–7.PubMedCrossRef

Goodwin WJ. Distant metastases from oropharyngeal cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:222–3.PubMedCrossRef

Brochet F, Bairati I, Roy J, Gelinas M, Nabid A, Tetu B, et al. Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer. Bull Cancer Radiother. 1996;83:8–11.PubMed

Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer. 2008;123:2390–6.PubMedCrossRef

Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks Jr WL. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg. 2009;17:88–94.PubMedCrossRef

Lin DT, Cohen SM, Coppit GL, Burkey BB. Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am. 2005;38:59–74.PubMedCrossRef

Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol. 2006;42:275–80.PubMedCrossRef

Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180–97.PubMedCrossRef

10.

Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008;97:649–52.PubMedCrossRef

11.

Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139–48.PubMedCrossRef

12.

Schick F, Whole-body MRI. at high field: technical limits and clinical potential. Eur Radiol. 2005;15:946–59.PubMedCrossRef

13.

Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications, and future applications. Semin Musculoskelet Radiol. 2001;5:5–20.PubMedCrossRef

14.

Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005;185:711–6.PubMedCrossRef

15.

Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging. 2007;26:498–509.PubMedCrossRef

16.

Squillaci E, Manenti G, Mancino S, Ciccio C, Calabria F, Danieli R, et al. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT – initial clinical experience. Abdom Imaging. 2008;33:676–88.PubMedCrossRef

17.

Lo GG, Ai V, Au-Yeung KM, Chan JK, Li KW, Chien D. Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J. 2008;14:90–6.PubMed

18.

Schmidt GP, Wintersperger B, Graser A, Baur-Melnyk A, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol. 2007;42:449–59.PubMedCrossRef

19.

Willinek WA, Schild HH. Clinical advantages of 3.0T MRI over 1.5T. Eur J Radiol. 2008;65:2.PubMedCrossRef

20.

Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199–206.PubMedCrossRef

21.

Ng SH, Chan SC, Yen TC, Chang JT, Liao CT, Ko SF, et al. (2009) Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965–76PubMedCrossRef

22.

Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43:557–64.PubMedCrossRef

23.

Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632–42.PubMedCrossRef

24.

Ng SH, Chan SC, Liao CT, Chang JT, Ko SF, Wang HM, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969–79.PubMedCrossRef

25.

Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24:4371–6.PubMedCrossRef

26.

Yeh DW, Lee KS, Han J, Yi CA, Lee HY, Chung MJ, et al. Mediastinal nodes in patients with non-small cell lung cancer: MRI findings with PET/CT and pathologic correlation. AJR Am J Roentgenol. 2009;193:813–21.PubMedCrossRef

27.

Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190–5.PubMedCrossRef

28.

Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136–43.PubMed

29.

Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009;19:634–42.PubMedCrossRef

30.

Xu GZ, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head Neck. 2011;33:87–94PubMedCrossRef

31.

Haerle SK, Strobel K, Hany TF, Sidler D, Stoeckli SJ. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck. 2010;32:319–25.PubMed

32.

Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1199–205.PubMedCrossRef

33.

Lauenstein TC, Goehde SC, Herborn CU, Treder W, Ruehm SG, Debatin JF, et al. Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR Am J Roentgenol. 2002;179:445–9.PubMed

34.

Frericks BB, Meyer BC, Martus P, Wendt M, Wolf KJ, Wacker F. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging. 2008;27:538–45.PubMedCrossRef

35.

Devaraj A, Cook GJ, Hansell DM. PET/CT in non-small cell lung cancer staging – promises and problems. Clin Radiol. 2007;62:97–108.PubMedCrossRef

36.

Bakheet SM, Amin T, Alia AG, Kuzo R, Powe J. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med. 1999;24:995–7.PubMedCrossRef

37.

Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.PubMedCrossRef

38.

Chan SC, Chang JT, Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol. 2009;45:52–8.PubMedCrossRef

39.

Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79:747–55PubMedCrossRef

40.

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;73:764–71.PubMedCrossRef

41.

Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–84.PubMedCrossRef

42.

Jaffe TA, Yoshizumi TT, Toncheva G, Anderson-Evans C, Lowry C, Miller CM, et al. Radiation dose for body CT protocols: variability of scanners at one institution. AJR Am J Roentgenol. 2009;193:1141–7.PubMedCrossRef

43.

Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosim. 2010;139:208–13.CrossRef

Titel: 18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study
verfasst von: Sheng-Chieh Chan
Hung-Ming Wang
Tzu-Chen Yen
Chien-Yu Lin
Shy-Chyi Chin
Chun-Ta Liao
Yau-Yau Wai
Jiun-Jie Wang
Shu-Hang Ng
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1824-y

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

What we have learned from Fukushima

90Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT)

Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions

Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer